Konekte ak nou

EU

#JunckerPlan sipòte prevansyon maladi kwonik nan #Finland

SHARE:

pibliye

Depi 5 ane

on

Nou itilize enskripsyon ou pou bay kontni nan fason ou te konsanti ak amelyore konpreyansyon nou sou ou. Ou ka koupe abònman nan nenpòt ki lè.

Plan Envestisman pou Ewòp, oswa Juncker Plan, is backing a €20 million European Investment Bank (EIB) loan to Finnish company Nightingale Health. The company will use the financing to further develop its blood analysis technology, which facilitates the detection and prevention of chronic diseases.

Jobs, Growth, Investment and Competitiveness Vice President Jyrki Katainen, who attended the signature event in Helsinki, said: "Europe invests heavily in education and science as we believe that putting a strategic effort into these areas can reap huge benefits. This commitment has resulted in Europe's position today as a world leader in cutting edge medical research. We are delighted that the Investment Plan for Europe is fostering the development of Nightingale's technology which has the potential to add significant value to European healthcare."

Nightingale's innovative blood analysis technology can detect early signs of chronic diseases, improving for example the assessment of a person's future risk of developing heart disease or type 2 diabetes. A press release is available isit la. As of December 2018, the European Fund for Strategic Investments (EFSI), at the heart of the Juncker Plan, had already mobilized €371.2 billion of additional investments, including €7.8bn in Finland.

Pataje atik sa a:

Sijè ki gen rapò:
EU Reporter pibliye atik ki soti nan yon varyete sous deyò ki eksprime yon pakèt pwen de vi. Pozisyon yo pran nan atik sa yo pa nesesèman sa yo nan EU Reporter.
reklam

Tendans